EviCure
Extracellular Vesicles-based Platform for the Treatment of Cancer
Company Overview
Snapshot
Founded in February 2023, EviCure operates with 1–10 employees. The company has raised $760.7K across four funding rounds from one investor.
Business overview
EviCure is a Health Tech & Life Sciences company developing a novel extracellular vesicle (EV)-based platform technology for cancer treatment. The company leverages AI capabilities and sophisticated human cancer disease models to conduct in-depth comparative analyses of stem cell subpopulations and secreted EVs, aiming to achieve robust and specific anti-tumor effects against a wide range of solid tumors. EviCure's EVs can also function as vehicles for targeted delivery of RNA-based therapies, peptides, and small therapeutic molecules. Their product, PL-Ex-1, is designed as an EV treatment against lung cancer, offering a safe, cost-effective, mutation-agnostic, and stage-independent solution for various lung and other solid tumors.
Log in to access full profile ›Company Intelligence Q&A
- What is EviCure's primary focus in cancer treatment?
- EviCure is developing a novel extracellular vesicle (EV)-based platform technology for cancer treatment, utilizing AI and human cancer disease models to achieve robust and specific anti-tumor effects against solid tumors.
- What is the total capital raised by EviCure?
- EviCure has raised a total of $760.7K across four funding rounds.
- Which investor has participated in EviCure's funding rounds?
- Peregrine Ventures has participated in EviCure's funding rounds, including an investment in January 2024.
- What is PL-Ex-1?
- PL-Ex-1 is the first product on EviCure’s platform, designed as an EV treatment against lung cancer, aiming to provide a safe, cost-effective, mutation-agnostic, and stage-independent treatment for various lung and other solid tumors.